Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 12, 4911-4921
Abstract
Purpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated. Patients and Methods: The medical records of patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated. Results: Forty-one patients with a median age of 76 years were analyzed. The overall response rate was 26.8%. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 8.1 months, respectively. While the median PFS of 4.7 and 2.8 months in the sensitive relapse and the refractory relapse group differed significantly (P=0.043), respectively, the median OS of 10.7 and 6.8 months in the respective relapse groups did not indicate a statistically significant difference (P=0.24). The median PFS in a group with a modified Glasgow prognostic score (mGPS) of 0 and a group with a mGPS 1 or 2 were 4.5 and 1.6 months (P=0.052), respectively, and the median OS in the respective mGPS groups were 10.7 and 4.4 months (P=0.034). Multivariate analysis identified good performance status, limited disease, and mGPS 0 as favorable independent predictors of PFS and OS of AMR monotherapy. Grade 3 or higher neutropenia was observed in 23 patients (56%), and febrile neutropenia was observed in nine patients (22%). Non-hematological toxic effects were relatively mild, and pneumonitis and treatment-related deaths were not observed. Conclusion: AMR is an effective and feasible regimen for elderly patients with relapsed SCLC after CE therapy.Keywords
This publication has 48 references indexed in Scilit:
- Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung CancerJournal of Thoracic Oncology, 2012
- Amrubicin for treating elderly and poor-risk patients with small-cell lung cancerInternational Journal of Clinical Oncology, 2010
- Trends in Lung Cancer Incidence by Histological Type in Osaka, JapanJapanese Journal of Clinical Oncology, 2008
- Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702British Journal of Cancer, 2007
- Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) studyInvestigational New Drugs, 2006
- A Statistical Study of Lung Cancer in the Annual of Pathological Autopsy Cases in Japan, from 1958 to 1997, with Reference to Time Trends of Lung Cancer in the WorldJapanese Journal of Cancer Research, 2002
- A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA ComplexJapanese Journal of Cancer Research, 1998
- Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor CellsJapanese Journal of Cancer Research, 1998
- Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor XenograftsJapanese Journal of Cancer Research, 1989